In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vaccinex Inc.

www.vaccinex.com

Latest From Vaccinex Inc.

Finance Watch: Vaccinex, Aridis Launch August's First US IPOs As The Summer Simmer Slows

The summer slowdown finally seems to have hit the US biopharma IPO market; after a hot July with nine offerings, there were just two during the first half of August. Also, Zogenix leads recent follow-ons with a $312m offering; venture capital planted in UK biotechs – Orchard and Blueberry.

Financing Business Strategies

Laquinimod Disappoints Again, This Time In Huntington's Disease

Laquinimod fails to impress in a Phase II study in Huntington's disease, adding to a series of clinical trial setbacks over past years for the potential oral immunomodulator.

 

Clinical Trials Neurology

Ionis/Roche's Huntington's Drug 'Next Spinraza'?

Further details of a Phase I/II study results are raising hopes that it could be the first disease-modifying treatment for the disease, but it is not yet known whether the reduction in Huntintin seen will translate into a clinical benefit.

Clinical Trials Research & Development

Roche's Neuroscience Franchise Gets Lift From Huntington's Breakthrough

Roche is aiming to bolster its future neuroscience franchise with another potential breakthrough product in neurology to add to its clinical-stage efforts in Alzheimer's disease, and its success in developing the first therapy for primary progressive multiple sclerosis, Ocrevus.

Clinical Trials Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vaccinex Inc.
  • Senior Management
  • Maurice Zauderer, PhD, Pres. & CEO
    Scott E Royer, CFO
    Ernest S Smith, PhD, VP, Research & CSO
    John E Leonard, PhD, SVP, Dev.
    Raymond E Watkins, SVP & COO
  • Contact Info
  • Vaccinex Inc.
    Phone: (585) 271-2700
    1895 Mt. Hope Ave.
    Rochester, NY 14620
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register